Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM10 | O14672 | 1/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 5/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1365841 | 0.87 | ADAM10 (0.62) | ADAM10ERBB2TDP1SLC6A5ALDH1A1 | |
| SCHEMBL12145005 | 0.85 | ADAM10 (0.64) | ADAM10ERBB2TDP1SLC6A5ALDH1A1 | |
| SCHEMBL1366458 | 0.85 | ADAM10 (0.64) | ADAM10ERBB2TDP1SLC6A5ALDH1A1 | |
| SCHEMBL1366407 | 0.77 | ADAM10 (0.47) | ADAM10ERBB2ALDH1A1LMNAMEN1 | |
| SCHEMBL17309090 | 0.76 | ADAM10 (0.62) | ADAM10ERBB2TDP1SLC6A5ALDH1A1 | |
| SCHEMBL1365231 | 0.76 | ADAM10 (0.76) | ADAM10ERBB2TDP1SLC6A5ALDH1A1 | |
| SCHEMBL12144988 | 0.76 | ADAM10 (0.76) | ADAM10ERBB2TDP1SLC6A5ALDH1A1 | |
| SCHEMBL12145002 | 0.74 | ADAM10 (0.59) | ADAM10ERBB2TDP1SLC6A5ALDH1A1 | |
| SCHEMBL1364214 | 0.74 | ADAM10 (0.76) | ADAM10ERBB2TDP1SLC6A5ALDH1A1 | |
| SCHEMBL1365833 | 0.74 | ADAM10 (0.76) | ADAM10ERBB2TDP1SLC6A5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10226459-B2 | Aza spiro alkane derivatives as inhibitors of metalloproteases | INCYTE HOLDINGS CORPORATION (US) | 2019-03-12 | — | — | US | disclosed |
| US-20180153882-A1 | AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases | INCYTE CORPORATION | 2018-06-07 | — | — | US | disclosed |
| US-9801877-B2 | AZA spiro alkane derivatives as inhibitors of metalloproteases | INCYTE CORPORATION (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170035751-A1 | AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases | INCYTE CORPORATION | 2017-02-09 | — | — | US | disclosed |
| US-9403775-B2 | AZA spiro alkane derivatives as inhibitors of metalloproteases | INCYTE CORPORATION (US) | 2016-08-02 | — | — | US | disclosed |
| EP-3020402-A1 | AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLPROTEASES | Incyte Holdings Corporation (US) | 2016-05-18 | — | — | EP | disclosed |
| EP-1622569-B1 | AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLPROTEASES | INCYTE CORP (US) | 2015-12-02 | — | — | EP | disclosed |
| US-20140187530-A1 | AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases | INCYTE CORPORATION (US) | 2014-07-03 | — | — | US | disclosed |
| US-8637497-B2 | AZA spiro alkane derivatives as inhibitors of metalloproteases | INCYTE CORPORATION (US) | 2014-01-28 | — | — | US | disclosed |
| EP-2617419-A1 | Aza spiro alkane derivatives as inhibitors of metallproteases | Incyte Corporation (US) | 2013-07-24 | — | — | EP | disclosed |
| US-20110288068-A1 | AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLOPROTEASES | INCYTE CORPORATION | 2011-11-24 | — | — | US | disclosed |
| US-8039471-B2 | Aza spiro alkane derivatives as inhibitors of metalloproteases | INCYTE CORPORATION (US) | 2011-10-18 | — | — | US | disclosed |
| US-7723349-B2 | N-hydroxy-5-methyl-6-{[4-(3-methylphenyl)piperazin-1-yl]carbonyl}-5-azaspiro[2.5]octane-7-carboxamide for example; treating arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions | INCYTE CORPORATION (US) | 2010-05-25 | — | — | US | disclosed |
| US-20090124649-A1 | AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLOPROTEASES | INCYTE CORPORATION (US) | 2009-05-14 | — | — | US | disclosed |
| US-20040259896-A1 | N-hydroxy-5-methyl-6-{[4-(3-methylphenyl)piperazin-1-yl]carbonyl}-5-azaspiro[2.5]octane-7-carboxamide for example; treating arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions | INCYTE CORPORATION | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288068-A1 | AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLOPROTEASES | MMP9, MMP3, MMP12 | ADAM10 29/4885ERBB2 2841/4885TDP1 1093/4885 |
| US-10226459-B2 | Aza spiro alkane derivatives as inhibitors of metalloproteases | MMP9, MMP3, MMP12 | ADAM10 29/4885ERBB2 2841/4885TDP1 1093/4885 |
| US-20170035751-A1 | AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases | MMP9, MMP3, MMP12 | ADAM10 29/4885ERBB2 2841/4885TDP1 1093/4885 |
| US-20090124649-A1 | AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLOPROTEASES | MMP9, MMP3, MMP12 | ADAM10 29/4885ERBB2 2841/4885TDP1 1093/4885 |
| US-20140187530-A1 | AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases | MMP9, MMP3, MMP12 | ADAM10 29/4885ERBB2 2841/4885TDP1 1093/4885 |
| US-20040259896-A1 | N-hydroxy-5-methyl-6-{[4-(3-methylphenyl)piperazin-1-yl]carbonyl}-5-azaspiro[2.5]octane-7-carboxamide for example; treating arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions | MMP9, MMP25, HDAC5 | ADAM10 258/4885ERBB2 2369/4885TDP1 2162/4885 |
| US-20180153882-A1 | AZA Spiro Alkane Derivatives as Inhibitors of Metalloproteases | MMP9, MMP3, MMP12 | ADAM10 29/4885ERBB2 2841/4885TDP1 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.